Aprea Therapeutics Inc (APRE NASDAQ) stock market data APIs
$1.4951
0.06(4%)
as of April 23, 2025
Aprea Therapeutics Inc Financial Data Overview
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is APR-1051, which is in Phase 1 clinical trial for treatment of advanced solid tumors with biomarkers that may predict sensitivity to WEE1 inhibition. Its pipeline includes the ATRN-119, an ATR inhibitor that is in a Phase 1/2a clinical trials for treating advanced solid tumors having at least one mutation in a defined panel of DDR-related genes. It also includes an early-stage program, which is in lead optimization stage for an undisclosed DNA-damage response ("DDR") target. The company is headquartered in Doylestown, Pennsylvania.
Prev. Close
1.4951
Open
1.553
High
1.553
Low
1.4944
52 wk Range
1.412-5.9
Market Cap
8 397 K
Shares Outstanding
5 435 K
Revenue
1 503 K
EPS
-0.49
Beta
1.621
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aprea Therapeutics Inc data using free add-ons & libraries
Get Aprea Therapeutics Inc Fundamental Data
Aprea Therapeutics Inc Fundamental data includes:
- Net Revenue: 1 503 K
- EBITDA: -14 297 337
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-24
- EPS/Forecast: -0.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aprea Therapeutics Inc News
New
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-...
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative tre...
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncol...
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncolo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
